Given the success of PSMA-targeted therapies in prostate cancer, PSMA-targeting agents could be investigated as a potential therapeutic approach in RCC, particularly in ccRCC, where PSMA expression is associated with tumor aggressiveness. This evidence concerns the gene FOLH1 and neoplasm.